Summary
Interest in the economic evaluation of drug treatments is steadily increasing, but the impact of such evaluations on decisions concerning the use of drugs is unclear. In this article I examine different decision and policy situations where economic evaluations of drug treatments could potentially be used. Economic evaluations may be used as an aid to the development of treatment guidelines, decisions within healthcare organisations. and decisions relating to approval, reimbursement and pricing.
Economic evaluations appear to be most useful in the development of treatment guidelines and as an aid to reimbursement decisions. The incentive to use economic evaluations embodied in the healthcare system is also important. It is argued that it is too early to introduce regulations that require the use of economic evaluations in, for example, reimbursement decisions. A more cautious approach might be preferred, where economic evaluations are used more selectively until the methodology and the field have developed further.
Similar content being viewed by others
References
Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications, 1987
Weinstein MC, Zeckhauser R. Critical ratios and efficient allocation. J Public Econ 1973; 2: 147–57
Mishan EJ. Cost-benefit analysis. 2nd ed. New York: Praeger, 1976
Baumol WJ. Economic theory and operations analysis. 3rd ed. London: Prentice Hall, 1972
Socialstyrelsens kommitte för läketnedelsbehandling. Rekommendationer från ett expertmöte: individualiserad hypertonibehandling, Lakartidningen 1990; 87: 2255–8
Johannesson M. The Australian guidelines for subsidisation of pharmaceuticals: the road to cost-effcctive drug prescribing? PharmacoEconomics 1992; 2: 355–62
Manning WG, Keeler EB, Newhouse JP, et al. The costs of poor health habits. Cambridge (MA): Harvard University Press, 1991
Henry D. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals. PharmacoEconomics 1992; 1: 54–67
Aristides M, Mitchell A. Applying the Australian guidelines for the reimbursement of pharmaceuticals. PharmacoEconomics 1994; 6: 196–201
Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto: Ministry of Health, 1994
Detsky AS. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. PharmacoEconomics 1993; 3: 354–61
Drummond MF, Rutten F, Brenna A, et al. Economic evaluation of pharmaceuticals: a European perspective. PharmacoEconomics 1993; 4: 173–86
van Hout B, Rutten F. Economic appraisal of health technology in the European community. In: Schubert F, editor. Proceedings of a Canadian collaborative workshop on pharmacoeconomics. Princeton (NJ): Escerpta Medica Inc., 1993: 8–13
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johnnnesson, M. Economic Evaluation of Drugs and its Potential Uses in Policy Making. Pharmacoeconomics 8, 190–198 (1995). https://doi.org/10.2165/00019053-199508030-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199508030-00003